Business Wire

SIGFOX

28.2.2020 12:18:09 CET | Business Wire | Press release

Share
An Post, the Irish Leading Mails, Parcels and Ecommerce Logistics Company, Revolutionise Their Supply Chain

An Post, the leading mails, parcels and ecommerce logistics company in Ireland, has contracted VT-IoT, the operator of Ireland’s Sigfox 0G network to revolutionise their supply chain with IoT tracking devices as part of their innovative and fast-moving digital transformation strategy.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200228005183/en/

As masters of delivery, An Post Mails & Parcels is rapidly changing from the old world of traditional letters to the new world of ecommerce parcel logistics and B2B services for Irish and international businesses. An Post runs Ireland’s largest fleet, including the country’s largest fleet of electric vehicles. It recently opened its new fully automated Dublin Parcel Hub and its operational infrastructure includes a large volume of returnable transport units such as roll cages and containers.

To provide an efficient and cost-effective service, An Post require a systematically integrated operational process. The roll cages and containers in which parcels are transported must be available every day in the required quantities in the Company’s mails hubs across the country.

With the advance of revolutionary Internet of Things (IoT) technology, VT and Sigfox are providing An Post with the solution they need to optimise their supply chain. Smart tracking devices empower An Post to monitor the location of their assets nationwide, even outside their own supply chain. Using Sigfox, the world’s leading IoT service provider and first global 0G network operator, has eliminated the barriers associated with traditional tracking technologies: price, battery life and coverage, by providing low cost, low power connectivity over a single global network today available in more than 70 countries.

“VT’s state-of-the-art solution has resulted in significantly increased transparency in our postal distribution network, ensuring world class quality of service for our customers and lower operational costs through improved containerisation efficiency”, explains Mark Devine, National Engineering Maintenance & Performance Manager, An Post .

Our collaboration with An Post is an exciting step forward into the future of industrial IoT and a key milestone toward connecting billions of IoT devices globally on the Sigfox 0G network. We are confident our solutions have the power to truly revolutionise the way logistics and supply chain companies do business, resulting in significantly reduced costs and increased efficiencies .” Mark Bannon, CEO, VT.

““We are delighted to support An Post in this new era of industry 4.0, where we are making the once untraceable now entirely visible to organisations. We continue to deliver benefits to Postal organisations, like An Post in Ireland, DHL in Germany and Posti in Finland. This is a key vertical for Sigfox, where we strive to deliver value and thought leadership in Global Supply Chain & Logistics." Glen Robinson, SVP Global Sales & Marketing, Sigfox.

About An Post

An Post provides world-class mails, e-commerce parcels, financial and communications services to national and international business. It delivers two million items of mail to 2.2 million address points nationwide every working day, as well as evening and weekend parcels deliveries.

About VT

VT is a 0G IoT network operator and a pioneer of IoT solutions within the Supply Chain and Aerospace markets. Our purpose is to empower our enterprise users to transform their business models and operations through our leading-edge device to cloud 0G solutions. Our nationwide Sigfox IoT telecoms network currently delivers over 95% geographical coverage to Ireland – we are passionate about enabling every person, home and business to benefit from 0G IoT.

About Sigfox

Sigfox is the initiator of the 0G network and the world’s leading IoT (Internet of Things) service provider. Its global network allows billions of devices to connect to the Internet, in a straightforward way, while consuming as little energy as possible. Sigfox’s unique approach to device-to-cloud communications addresses the three greatest barriers to global IoT adoption: cost, energy consumption and global scalability.

Today, the network is available in 70 countries, with 1 billion people covered. ISO 9001 certified and surrounded by a large ecosystem of partners and IoT key players, Sigfox empowers companies to move their business model towards more digital services, in key areas such as Asset Tracking and Supply Chain. Founded in 2010 by Ludovic Le Moan and Christophe Fourtet, the company is headquartered in France and has offices in Madrid, Munich, Boston, Dallas, San Jose, Dubai, Singapore, Sao Paulo and Tokyo.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye